Penn Medicine Provider
Pathology and Laboratory Medicine
Ira J. Bleiweiss, MD
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Call 800-789-7366

About me

  • Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Saint George's University
  • Residency: Mount Sinai Medical Center
  • Fellowship: Mount Sinai Medical Center
  • Fellowship: Memorial Sloan-Kettering Cancer Center

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Bleiweiss is a Penn Medicine physician.

Qualifications and experience

My research

Tondi Resta I, Nelson ND, Toorens E, Bleiweiss IJ, Nayak A Mucinous Cystadenocarcinomas of the Breast Exhibit Heterogeneous Genomic Profile as Triple Negative Breast Cancer, Harbor Alterations in PIK3CA, PTEN, AKT1, and GNAS Genes, and May Not Be Indolent , Int J Surg Pathol: 2025

Avalos Hernandez SR, Hu T, Dumoff KL, Vickery JM Bleiweiss IJ, Nayak A Invasive lobular carcinoma with extracellular mucin (ILCEM) presenting at distant metastases and recurrences may exhibit triple negative phenotype , Mod Pathol: 2025

Narasimhamurthy M, Le A, Boruah N, Moses R, Kelly G, Bleiweiss I, Maxwell KN, Nayak A. Clinicopathologic Features of Breast Tumors in Germline TP53 Variant-Associated Li-Fraumeni Syndrome , Am J Surg Pathol, 49: 2025,195-205

Nayak A, Demarest K, Bleiweiss IJ, Shah PD Pathologic response of metaplastic carcinomas to KEYNOTE-522 regimen: correlation with histological subtypes. , Mod Pathol: 2025

Tondi Resta I, Hu T, Dumoff KL, Avalos Hernandez SR, Vickery JM Bleiweiss IJ, Nayak A Tubulopapillary carcinomas of the breast: histopathologic features, immunohistochemical staining with p16, p53, and SOX10, and molecular findings , Mod Pathol: 2025

Tondi Resta I, Goldbach MM, Tchou JC, Bleiweiss IJ, Nayak A Pathologic Features and Residual Cancer Burden (RCB) after Neoadjuvant Endocrine Therapy (NET) in Hormone Receptor Positive Breast Cancer (HR+ BC). , Mod Pathol: 2024

Lennerz JK, Pantanowitz L, Amin MB, et al. Ensuring remote diagnostics for pathologists: an open letter to the US Congress. , Nat Med, 12: 2022,2453-2455

Narasimhamurthy M, Good M, Desai H, Le A, Bleiweiss IJ, Maxwell K, Nayak A Clinico-pathological features of breast tumors associated with Li-Fraumeni Syndrome , Mod Pathology, 35: 2022,196-198

Zhao X, Nayak A, Bleiweiss IJ Does the status of the tumor bed at surgical margins affect local recurrence and overall prognosis in patients undergoing lumpectomy status post neoadjuvant therapy , Mod Pathology, 35: 2022,224-225

Hawrot K, Shulman LN, Bleiweiss IJ, Wilkie EJ, Jankowitz RC, Laughlin AI Time to Treatment Initiation for Breast Cancer during the 2020 COVID-19 Pandemic , JCO Oncology Practice, 17(9): 2021,534-540